Table 3.
Risk factors for 28 days mortality in ACLF patients with variceal bleeding (n=61)*
| Variable | Univariable analysis |
Multivariable analysis |
||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age (years) | 0.98 (0.94–1.02) | 0.251 | ||
| Gender, male | 1.38 (0.47–4.02) | 0.554 | ||
| WBC (×103/uL) | 1.00 (0.99–1.01) | 0.096 | ||
| Hb (g/dL) | 1.00 (0.87–1.15) | 0.955 | ||
| Platelets (×103/uL) | 1.00 (0.99–1.01) | 0.605 | ||
| Albumin (g/dL) | 0.37 (0.16–0.88) | 0.023 | 0.72 (0.30–1.71) | 0.455 |
| Bilirubin (mg/dL) | 1.03 (0.99–1.07) | 0.127 | ||
| AST (IU/L) | 1.00 (0.99–1.01) | 0.538 | ||
| ALT (IU/L) | 1.00 (0.99–1.01) | 0.182 | ||
| Prothrombin time (INR) | 1.68 (1.21–2.33) | 0.002 | ||
| CRP (mg/dL) | 0.99 (0.91–1.08) | 0.815 | ||
| Sodium (mEq/L) | 1.01 (0.96–1.07) | 0.673 | ||
| Creatinine (mg/dL) | 1.00 (0.82–1.22) | 0.970 | ||
| Ascites, presence | 1.21 (0.29–5.16) | 0.792 | ||
| HE, presence | 1.82 (0.68–4.86) | 0.231 | ||
| MELD | 1.06 (1.01–1.11) | 0.010 | ||
| CTP score | 1.32 (1.08–1.62) | 0.006 | ||
| CLIF-SOFA | 1.33 (1.21–1.47) | <0.001 | 1.32 (1.19–1.46) | <0.001 |
| Etiology of CLD | ||||
| Viral, HBV or HCV | 1 | |||
| Alcohol | 1.56 (0.37–6.66) | 0.547 | ||
| Viral+alcohol | 3.24 (0.45–23.09) | 0.241 | ||
| Others | 0.01 (0.01–0.02) | 0.985 | ||
ACLF, acute on chronic liver failure; HR, hazard ratio; CI, confidence interval; WBC, white blood cell; Hb, hemoglobin; AST, aspartate transaminase; ALT, alanine aminotransferase; INR, international ratio; CRP, C-reactive protein; HE, hepatic encephalopathy; MELD, model of end-stage liver disease; CTP, Child-Turcotte-Pugh; CLIF SOFA, the chronic liver failure-sequential organ failure assessment; CLD, chronic liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus.
*
Subjects (n=61), event: death (n=25).